Acrux(OTC) ARUXF

Acrux Limited specializes in the global development and commercialization of generic and topical pharmaceutical products. The company focuses on testosterone therapies and estradiol sprays, catering to both men and women in various international markets.

Products and Services

• Diverse testosterone therapies including oral tablets and transdermal patches
• Estradiol sprays marketed as Evamist and Lenzetto for menopausal symptoms
• Topical gels and subcutaneous pellets for hormone replacement therapy

Growth Outlook

• Recent quarterly revenue reached AUD 2.9 million, indicating strong market demand
• Expansion into international markets enhances growth potential
• Focus on innovative therapies positions the company for future success

Financial Highlights

• Trailing twelve months revenue of AUD 8.3 million reflects a growing customer base
• Gross profit margin of 92.56% in the latest quarter demonstrates operational efficiency
• Cash and cash equivalents increased to AUD 1.7 million, providing liquidity for operations

Acrux Limited, established in 1998 and headquartered in West Melbourne, Australia, operates in the biotechnology sector. The company has a dedicated workforce of 43 employees and is committed to addressing the needs of patients with low testosterone levels and menopausal symptoms. The recent financial performance indicates a positive trajectory, with significant revenue growth and a strong gross profit margin. The focus on innovative therapies and expansion into new markets positions Acrux Limited as a compelling option for investors interested in the biotechnology field.